![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
DDIs (drug-drug interactions) in the evolving HCV treatment landscape
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
Saye Khoo
Institute of Translational Medicine
University of Liverpool
![Pharm1.gif](../images/052714/052714-3/Pharm1.gif)
![Pharm2.gif](../images/052714/052714-3/Pharm2.gif)
![Pharm3.gif](../images/052714/052714-3/Pharm3.gif)
![Pharm4.gif](../images/052714/052714-3/Pharm4.gif)
![Pharm5.gif](../images/052714/052714-3/Pharm5.gif)
![Pharm6.gif](../images/052714/052714-3/Pharm6.gif)
![Pharm7.gif](../images/052714/052714-3/Pharm7.gif)
![Pharm8.gif](../images/052714/052714-3/Pharm8.gif)
![Pharm9.gif](../images/052714/052714-3/Pharm9.gif)
![Pharm10.gif](../images/052714/052714-3/Pharm10.gif)
![Pharm11.gif](../images/052714/052714-3/Pharm11.gif)
![Pharm12.gif](../images/052714/052714-3/Pharm12.gif)
![Pharm13.gif](../images/052714/052714-3/Pharm13.gif)
![Pharm14.gif](../images/052714/052714-3/Pharm14.gif)
![Pharm15.gif](../images/052714/052714-3/Pharm15.gif)
![Pharm16.gif](../images/052714/052714-3/Pharm16.gif)
![Pharm17.gif](../images/052714/052714-3/Pharm17.gif)
![Pharm18.gif](../images/052714/052714-3/Pharm18.gif)
![Pharm19.gif](../images/052714/052714-3/Pharm19.gif)
![Pharm20.gif](../images/052714/052714-3/Pharm20.gif)
![Pharm21.gif](../images/052714/052714-3/Pharm21.gif)
![Pharm22.gif](../images/052714/052714-3/Pharm22.gif)
![Pharm23.gif](../images/052714/052714-3/Pharm23.gif)
![Pharm24.gif](../images/052714/052714-3/Pharm24.gif)
![Pharm25.gif](../images/052714/052714-3/Pharm25.gif)
![Pharm26.gif](../images/052714/052714-3/Pharm26.gif)
![Pharm27.gif](../images/052714/052714-3/Pharm27.gif)
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
May 19- 21, 2014, Washington, DC
Single-Dose Pharmacokinetics of Daclatasvir (DCV; BMS-790052) in Subjects With Hepatic Impairment Compared With Healthy Subjects......http://www.natap.org/2011/AASLD/AASLD_78.htm.....Bifano AASLD 2011
Daclatasvir (DCV; BMS-790052) Has No Clinically Significant Effect on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects.......http://www.natap.org/2011/AASLD/AASLD_77.htm Bifano AASLD 2011
CROI/2012: Assessment of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r http://www.natap.org/2012/CROI/croi_38.htm
15th Intl Wrkshp Clinical Pharm HIV Therapy ABT-450/Ritonavir +Ombitasvir + Dasabuvir: Drug Interactions Mediated by Transporters - (05/21/14)
The Effect of Hepatic Impairment on the Safety, Pharmacokinetics, and Antiviral Activity of GS-7977 in Hepatitis C Infected Subjects Treated for Seven Days.....http://www.natap.org/2012/EASL/EASL_47.htm Lawitz EASL 2012
15th Intl Wrkshp Clinical Pharm HIV Therapy Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/22/14)
15th Intl Wrkshp Clinical Pharm HIV Therapy Gilead - Transporters: Role in Clinical Development of HCV Compounds - (05/23/14)
AASLD: Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Moderate or Severe Hepatic Impairment - (11/11/13)
AASLD: Lack of a Clinically Important Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir (SOF) or Ledipasvir (LDV) in HCV-Uninfected Female Subjects - (11/11/13)
![Pharm28.gif](../images/052714/052714-3/Pharm28.gif)
![Pharm29.gif](../images/052714/052714-3/Pharm29.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|